<\/p>\n\n\n\n
The world of biotech and drug development has long relied on trial and error and statistical averages. While we often associate this approach with diseases like cancer or autoimmune disorders, it has left the immune system, one of the most important systems in the human body, among the least systematically understood in medicine.<\/p>\n\n\n\n
That gap is becoming harder to ignore. In the United States, funding cuts threaten to slow basic research at the very moment when the complexity of biological problems is increasing. As public support tightens, the pressure grows to build new kinds of infrastructure that can help translate scientific discovery into long-term medical progress.<\/p>\n\n\n\n
To understand some of these challenges more, I spoke with Noam Solomon, the co-founder and CEO of Immunai. The Israeli company has raised almost $300 million with the mission to create \u201cthe Google Maps of the immune system.\u201d<\/p>\n\n\n\n
And that mission is massive – requiring time and patience on a mathematically enormous scale.<\/p>\n\n\n\n
Immunai aggregates and analyzes vast amounts of single-cell data to understand how the immune system behaves over time and across conditions. The work may not deliver immediate breakthroughs, but it could shape how medicine, industry, and governments make decisions in the future.<\/p>\n\n\n\n
Ultimately, it will create what Solomon describes not as a dataset, but as a functional map of the immune system. The distinction matters: A map allows prediction, whereas a spreadsheet does not.<\/p>\n\n\n\n